MANP / E-Star BioTech - LARVOL DELTA

BOLD-HTN: To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: E-Star BioTech, LLC | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension (GlobeNewswire) - "E-Star BioTech, LLC...today announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension."

Trial status • Hypertension